Document text
Principal Investigator: Mary N. Carrington
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2022
Award: $156,177
Funding agency: National Cancer Institute
The SARS- CoV-2 Omicron variant (B.1.1.529) was the cause of a new surge of infections globally. With as many as 36 substitutions in the viral spike protein and 59 mutations in total throughout its genome, Omicron has been found to evade neutralization by infection- and vaccine-induced antibodies with unprecedented frequency and escape neutralization by most therapeutic monoclonal antibodies. Additional booster vaccine doses partially compensate for this effect, but the durability of such protective antibody response remains to be determined. Utilizing samples from prior SARS-CoV-2 infected, vaccinated, and both prior infected and vaccinated individuals, it was shown that circulating effector T cell responses and both CD4+ and CD8+ memory T cell responses were generally preserved to the Omicron variant. However, distinct from previous variants of concern (VOCs), such as Delta, a subset of individuals had reduced effector and memory T cell recognition to the Omicron spike protein relative to wild-type spike, with a particularly noticeable effect on spike-specific CD8+ T cell memory re- sponses. Booster doses enhanced the magnitude of responses to wild-type and Omicron spike, although did not completely mitigate the comparatively reduced T cell reactivity to Omicron in individual participants. These findings also raise the prospect that future SARS-CoV-2 variants may variably escape from antibody or T cell responses. They therefore support continued evaluation of second-generation vaccine approaches that induce robust T cell responses that target both variant spike and nonspike antigens in order to overcome current and future SARS-CoV-2 evolution.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Antibodies><Antibody Response><Antigens><Biological><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><COVID-19><COVID-19 infection><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 infection><COVID19 virus><CV-19><CV19><CoV-2><CoV2><Disease Outcome><Dose><Evaluation><Evolution><Frequencies><Future><Generations><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic defect><Genome><Immune Response Genes><Immune response><Immunological response><Individual><Infection><Investigators><Ir Gene><LYT3><Lytotoxicity><MAb Therapeutics><Molecular><Mutation><Participant><Proteins><Research Personnel><Researchers><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><T cell response><T memory cell><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Teff cell><Testing><Therapeutic Monoclonal Antibodies><Vaccinated><Vaccination><Vaccinee><Vaccines><Variant><Variation><Viral><Wuhan coronavirus><biologic><booster dose><booster shot><booster vaccine><comparative><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><cytotoxicity><effector T cell><genetic association><genetic resistance><genome mutation><hCoV19><host response><immune system response><immunogen><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><memory T lymphocyte><monoclonal antibody drugs><nCoV2><preservation><response><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><therapeutic mAbs><thymus derived lymphocyte><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine antibodies><vaccine induced antibodies><vaccine-induced antibodies><variants of concern>